Risdiplam for muscular atrophy, spinal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 6 registered trials.

Why this status

  1. 10 Feb 2022: Trial registered, NCT05232929
  2. 29 Mar 2022: Trial started, NCT05232929
  3. 31 Aug 2022: Trial registered, NCT05522361
  4. 6 Nov 2022: Trial started, NCT05522361

The trials

NCT02913482: Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

State
Completed
Phase
Phase 2
People
62 taking part
Started
23 Dec 2016
Primary completion
14 Nov 2019
Arms
Part 1 (Dose Finding): Risdiplam (RO7034067), Part 2 (Confirmatory): Risdiplam (RO7034067)
Results
Posted on the registry
  1. 23 Sep 2016: Trial registered
  2. 23 Dec 2016: Trial started
  3. 8 Jan 2021: Trial results posted
  4. 22 Dec 2023: Trial completed

NCT03032172: A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

State
Completed
Phase
Phase 2
People
174 taking part
Started
3 Mar 2017
Primary completion
7 Feb 2025
Arms
Risdiplam
Results
Posted on the registry
  1. 26 Jan 2017: Trial registered
  2. 3 Mar 2017: Trial started
  3. 7 Feb 2025: Trial completed
  4. 1 Oct 2025: Trial results posted

NCT03779334: A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

State
Under way
Phase
Phase 2
People
26 taking part
Started
7 Aug 2019
Primary completion
20 Feb 2023
Arms
Open-label Risdiplam
Results
Posted on the registry
  1. 19 Dec 2018: Trial registered
  2. 7 Aug 2019: Trial started
  3. 5 Mar 2024: Trial results posted

NCT05232929: Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

State
Completed
Phase
Phase 4
People
403 taking part
Started
29 Mar 2022
Primary completion
9 Oct 2026
Arms
Risdiplam
Results
None posted
  1. 10 Feb 2022: Trial registered
  2. 29 Mar 2022: Trial started
  3. 9 Oct 2026: Trial completed

NCT05522361: Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

State
State not given
Phase
Phase 4
People
10 planned
Started
6 Nov 2022
Primary completion
31 Dec 2025
Arms
Open-label crossover
Results
None posted
  1. 31 Aug 2022: Trial registered
  2. 6 Nov 2022: Trial started

NCT05808764: A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

State
Completed
Phase
Phase 2
People
11 taking part
Started
26 Apr 2024
Primary completion
4 May 2026
Arms
Risdiplam
Results
None posted
  1. 11 Apr 2023: Trial registered
  2. 26 Apr 2024: Trial started
  3. 4 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Evrysdi.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.